AN2 Therapeutics Inc (ANTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.89-1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ANTX — earnings miss
Dated 2026-05-11
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Enrollment progress is key to showing the drug works against a tough infection.
Supportive ifEnrollment in the Phase 2 trial shows steady progress and meets timelines.
Worry ifIf enrollment slows down or misses deadlines, data reporting will be late.
Why it matters: A partnership can improve resources and trust for the Chagas disease program.
Supportive ifA new partnership for the Chagas disease study has been announced.
Worry ifNo new partnerships are formed, limiting resources for the study.
Why it matters: Data readouts will show how well AN2-502998 and other programs work. This affects investor confidence.
Watch forGood results are coming from ongoing clinical trials.
Also watch forNegative or inconclusive data readouts from the trials.
Why it matters: Data readouts can validate the effectiveness of the treatments. This can boost confidence in the company's future.
Supportive ifThey will share many good data results soon. This will happen while they have enough cash.
Worry ifFailure to report any data readouts within the cash runway.
Why it matters: Good Phase 1 results would help AN2-502998 for chronic Chagas disease. This is an important need.
Supportive ifThe Phase 1 data for AN2-502998 shows good safety and effectiveness.
Worry ifThe data shows safety issues or that it may not work well.
Why it matters: Starting this trial is key for AN2's growth. It shows progress in treating a serious blood cancer.
Supportive ifThe Phase 2 trial for polycythemia vera starts in Q4 2026 as planned.
Worry ifThe trial does not start as expected due to regulatory delays.
Why it matters: Starting the Phase 2 study is key for AN2-502998's progress and market chance.
Supportive ifThe Phase 2 study for AN2-502998 starts as planned. This shows management's commitment.
Worry ifThe Phase 2 study is delayed or canceled. This shows possible problems with the drug.
Why it matters: These programs show the company's skill in developing its pipeline. This may attract more investors.
Supportive ifOne or more programs are moving into Phase 2 development.
Worry ifNo updates or delays in advancing programs into Phase 2.
Why it matters: Multiple data readouts can signal progress and efficacy of treatments. This can boost confidence.
Supportive ifRelease of positive data readouts for at least two programs before cash runway ends.
Worry ifNo data readouts released before cash runway ends.
Why it matters: Updates on the partnership could help develop and provide AN2-502998 for Chagas disease.
Supportive ifNew news about collaboration or funding from DNDi is coming.
Worry ifNo updates or signs of progress in the partnership with DNDi.
Why it matters: This trial could lead to the first FDA-approved treatment for a significant unmet need.
Supportive ifThe Phase 2 trial for AN2-502998 in chronic Chagas disease starts as planned in late 2026.
Worry ifThe trial initiation is delayed or cancelled.
Why it matters: Moving this candidate forward could add to AN2's pipeline and boost growth.
Supportive ifAN2 shares news about progress on the ENPP1 candidate for solid tumors.
Worry ifNo updates or progress reported on the ENPP1 candidate.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$283 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $567 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,560 loss on $10,000 · 45.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.